Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 487-495

  Yoshida, Hideo ^a,c   Okamura, Yosuke ^b,c   Watanabe, Naohide ^c   Ikeda, Yasuo ^b   Handa, Makoto ^c  

^a KOWA COMPANY LTD   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

GPIb V IX; PGE1; Phosphodiesterase 3 inhibitor; Shear induced platelet thrombus formation; VWF

Indexed keywords

6 [3 [3 CYCLOPROPYL 3 (2 HYDROXYCYCLOHEXYL)UREIDO]PROPOXY] 2(1H) QUINOLINE; ACETYLSALICYLIC ACID; COLLAGEN; CYCLIC AMP; CYCLIC GMP; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IX; GLYCOPROTEIN V; GS PROTEIN COUPLED RECEPTOR; K 134; OPC 33509; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROSTAGLANDIN E1; RISTOCETIN; TIROFIBAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ASPIRIN; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HEMOSTASIS; HUMANS; LIGANDS; PLATELET AGGREGATION; QUINOLINES; RISTOCETIN; SHEAR STRENGTH; TYROSINE; UREA; VON WILLEBRAND FACTOR;

EID: 79952525002     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-07-0439     Document Type: Article

References (29)

1. Feijge MA, Ansink K, Vanschoonbeek K, et al. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 2004; 67: 1559-1567. (Pubitemid 38388218)
2. Norgren L, Hiatt WR, Dormandy JA, et al.; TASC II Working Group. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-67.
3. Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-602.
4. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38: 710-713. (Pubitemid 37254796)
5. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008; 47: 330-336.
6. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157. (Pubitemid 30480490)
7. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297. (Pubitemid 26040846)
8. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666. (Pubitemid 28427584)
9. Kasirer-Friede A, Cozzi MR, Mazzucato M, et al. Signaling through GPIb/IX/V activates alpha IIb beta 3 independently of other receptors. Blood 2004; 103: 3403-3411. (Pubitemid 38525671)
10. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001; 20: 2120-2130. (Pubitemid 32410582)
11. Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost 2009; 7 (Suppl 1):17-20.
12. Akiyama H, Kudo S, Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985; 35: 1133-1140. (Pubitemid 15030826)
13. Minami N, Suzuki Y, Yamamoto M, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci 1997; 61: PL 383-389. (Pubitemid 28122473)
14. Sudo T, Tachibana K, Toga K, et al. Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59: 347-356. (Pubitemid 30015963)
15. Koga Y, Kihara Y, Okada M, et al. 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Bioorg Med Chem Lett. 1998; 8: 1471-1476.
16. Nishiya T, Kainoh M, Murata M, et al. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ibα under flow conditions: specific synergy of receptor-ligand interactions. Blood 2002; 100: 136-142. (Pubitemid 35177438)
17. Shenkman B, Savion N, Dardik R, et al. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000; 99: 353-361. (Pubitemid 30645689)
18. Mazzucato M, Cozzi MR, Pradella P, et al. Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow. Blood 2004; 104: 3221-3227. (Pubitemid 39507138)
19. Tschopp TB, Baumgartner HR. Platelet adhesion and mural platelet thrombus formation on aortic subendothelium of rats, rabbits, and guinea pigs correlate negatively with the vascular PGI2 production. J Lab Clin Med 1981; 98: 402-411. (Pubitemid 11049472)
20. Sun B, Le SN, Lin S, et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 2002; 40: 577-585.
21. Bodnar RJ, Xi X, Li Z, et al. Regulation of glycoprotein Ib-IX-von Willebrand factor interaction by cAMP-dependent protein kinase-mediated phosphorylation at Ser 166 of glycoprotein Ib(beta). J Biol Chem 2002; 277: 47080-47087. (Pubitemid 36159216)
22. Mazzucato M, Pradella P, Cozzi MR, et al. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002; 100: 2793-2800.
23. Yap CL, Hughan SC, Cranmer SL, et al. Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. J Biol Chem 2000; 275: 41377-41388.
24. Ichinohe T, Takayama H, Ezumi Y, et al. Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. J Biol Chem 1995; 270: 28029-28036.
25. Ryningen A, Jensen BO, Holmsen H. Role of autocrine stimulation on the effects of cyclic AMP on protein and lipid phosphorylation in collagen-activated and thrombin-activated platelets. Eur J Biochem 1999; 260: 87-96. (Pubitemid 29095698)
26. 2 in botrocetin/ VWF-induced aggregation of washed platelets. J Thromb Haemost 2004; 2: 2213-2222.
27. Pasini FL, Capecchi PL, Perri TD. Adenosine and chronic ischemia of the lower limbs. Vasc Med 2000; 5: 243-250. (Pubitemid 32117858)
28. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001; 52: 25-39. (Pubitemid 32835236)
29. Sinzinger H, Silberbauer K, Horsch AK, et al. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon? Prostaglandins 1981; 21: 49-51.